摘要
自16年前首次被证明静脉溶栓可有效治疗急性缺血性卒中以来,溶栓率一直不高。尽管很多试验证明了许多溶栓药物的疗效,但静脉注射用组织型纤溶酶原激活剂(rt-PA,0.9 mg.kg-1)几乎成为惟一用于溶栓治疗的溶栓剂。针对这种情况,研究者正在多方面对研究工作进行改进,包括使用新的溶栓药物。另外,研究者正在尝试用新的溶栓剂、低剂量的rt-PA、神经保护剂等减少症状性脑出血的危险。
Around 16 years have now elapsed since thrombolysis was first shown to be effective for treating acute ischemic stroke,but therapeutic uptake has been modest.Despite attempts to demonstrate efficacy of a number of thrombolytic agents,intravenous tissue plasminogen activator（rt-PA） at a dosage of 0.9 mg·kg^-1 is almost exclusively used for thrombolysis.Research efforts are being directed towards rectifying this situation in a number of ways including the use of alternative thrombolytic agents.Attempts are underway to reduce the risk of symptomatic intracerebral hemorrhage through the use of alternative thrombolytic agents,lower doses of tissue plasminogen activator,and neuroprotectants.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2012年第11期1237-1240,共4页
Chinese Journal of New Drugs
关键词
缺血性卒中
溶栓剂
重组组织纤溶酶原激活剂
症状性脑出血
神经保护剂
ischemic stroke
thrombolytic agents
recombinant tissue plasminogen activator（rt-PA）
symptomatic intracerebral hemorrhage（sICH）
neuroprotectant
